Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mepivacaine
Drug ID BADD_D01387
Description A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Indications and Usage For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Marketing Status approved; vet_approved
ATC Code N01BB03
DrugBank ID DB00961
KEGG ID D08181
MeSH ID D008619
PubChem ID 4062
TTD Drug ID D0WO8W
NDC Product Code 52932-0745
UNII B6E06QE59J
Synonyms Mepivacaine | Mepivacaina Braun | Isogaine | Meaverin | Mecain | Mepihexal | Mepivacain-Injektopas | Mepivacain Injektopas | Mepivacaine Hydrochloride | Mepivacaine Monohydrochloride | Mepivastesin | Polocaine | Scandinibsa | Scandonest | Scandicain | Scandicaine | Carbocaine | Carbocaïne | Isocaine
Chemical Information
Molecular Formula C15H22N2O
CAS Registry Number 96-88-8
SMILES CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acidosis14.01.03.002--
Aggression19.05.01.0010.000268%Not Available
Agitation19.06.02.001; 17.02.05.0120.000268%
Amnesia19.20.01.001; 17.03.02.0010.000179%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000268%
Anaphylactic shock10.01.07.002; 24.06.02.0040.000357%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000268%Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Asthenia08.01.01.001--Not Available
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.000357%Not Available
Brain hypoxia24.04.06.022; 22.02.02.010; 17.08.02.009--Not Available
Cardiac arrest02.03.04.0010.000357%
Cardiac output decreased13.14.02.001--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000179%Not Available
Chest pain22.12.02.003; 02.02.02.011; 08.01.08.0020.000179%Not Available
Chills15.05.03.016; 08.01.09.001--
Circulatory collapse24.06.02.0010.000179%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000179%
Discomfort08.01.08.0030.000179%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.001322%
Drug hypersensitivity10.01.01.0010.001000%Not Available
Drug ineffective08.06.01.0060.021828%Not Available
Dysarthria19.19.03.001; 17.02.08.0010.000268%
Dysgeusia17.02.07.003; 07.14.03.0010.000393%
Dysphagia07.01.06.0030.000268%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages